QUADRA Supports Broader Use For Tesaro's PARP Inhibitor Zejula
Study in late-line use of heavily pretreated ovarian cancer may bring labeling closer in line with competitors, yet with limited commercial impact, analysts say.
Study in late-line use of heavily pretreated ovarian cancer may bring labeling closer in line with competitors, yet with limited commercial impact, analysts say.